NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

IM Cannabis Corp. (IMCC) Stock Analysis

IM Cannabis Corp. (IMCC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

IMCC

$1.98

−$0.22 (−10.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMCC with… →

IMCC Key Statistics

As of Sep 4, 2026
Trading
Open
$2.37
Previous Close
$2.20
Day's Range
1.95–2.37
52-Week Range
1.95–77.10
Volume
91.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.10
Valuation
Market Cap
$1.20M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−75.78
Financials (FY)
Revenue (FY)
$54.73M+1.30%
Net Income (FY)
−$11.32M
Profit marginThe share of revenue left as profit after all costs and taxes.
−39.13%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
603.92K
1-Year Return
−3.41%
Dividend and dates
Avg Volume
208.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMCC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+42.45%
2025−40.37%
2024+8.82%
2023−63.38%
2022−97.08%
2021−57.18%
2020 (partial year)+294.74%

As of September 4, 2026.

IMCC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$54.73M−$11.32M−20.7%
2024$54.03M−$10.59M−19.6%
2023$48.80M−$9.50M−19.5%
2022$54.34M−$188.89M−347.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$54.73M$9.69M−$11.59M−$11.32M−20.7%
2024$54.03M$8.45M−$10.23M−$10.59M−19.6%
2023$48.80M$9.85M−$12.18M−$9.50M−19.5%
2022$54.34M$9.16M−$22.50M−$188.89M−347.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMCC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricIMCCDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.032.300.0x the median
Profit margin−39.13%−3.14%36.0 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

IM Cannabis Corp. (IMCC) is capitalised at $1.20M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 44 employees.

The most recent close on file for IMCC is $1.98, dated September 4, 2026. That is −$0.22 (−10.00%) against the previous close. The 52-week range on file runs from $1.95 to $77.10. The latest close sits 1.54% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $54.73M. Against the prior fiscal year total of $54.03M, that is a change of +1.30%. The same year closed with a net loss of $11.32M. The reported profit margin is −39.13%. That is 36 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −75.78.

Across the 4 fiscal years on file, revenue moves from $54.34M in 2022 to $54.73M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.03. On price-to-sales that is 0 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.1. Annualized volatility over the trailing 6 years is 1,182.38%. Over the trailing twelve months the price has returned −3.41%. Measured over 5 years, that is −60.83% a year compounded.

Growth & Income

No dividend is on file for IMCC.

The strongest complete calendar year on file is 2024 at +8.82%; the weakest is 2022 at −97.08%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is +42.45%.

Peer Comparison

IM Cannabis Corp. (IMCC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IM Cannabis Corp. IMCC $1.20M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. IM Cannabis Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About IM Cannabis Corp.

IM Cannabis Corp. engages in importation, distribution and sale of medical cannabis products in Israel and Germany. It provides medical cannabis dried flowers; and full-spectrum cannabis extracts under the IMC, BLKMT, and LOT420 brands. The company serves medical patients. IM Cannabis Corp. was founded in 2008 and is headquartered in Vancouver, Canada.

Visit website →